Stepwise Approach Using Combined Management in Patients with Congenital Heart Disease and Borderline Pulmonary Vascular Disease

Sang-Yun Lee, MD, Soo-Jin Kim, MD, Jae Sung Son, MD, Seong-Ho Kim, MD, and Chang-Ha Lee, MD

Department of Pediatrics, Department of Thoracic and Cardiovascular Surgery, Sejong Cardiovascular Institute, Bucheon, Department of Pediatrics, Konkuk University School of Medicine, Seoul, Korea

Background and Objectives: Despite remarkable advances in pediatric cardiology, pulmonary arterial hypertension associated with congenital heart disease remains a major problem. In the past decade new vasodilators have been introduced and appear to be effective in reducing pulmonary vascular resistance (PVR).

Subjects and Methods: From 2000 to 2011, we retrospectively reviewed the records of 22 patients who had congenital septal defects and borderline pulmonary vascular disease (PVD). The PVR in these patients was from 6 to 16 wood units · m², and/or the systolic pulmonary arterial pressure was more than 2/3 of the systemic arterial pressure.

Results: The median age was 16 years (range, 9 months-46 years). The median duration of follow-up was 7.4 years (range, 1.4-11.7 years). According to hemodynamic data and clinical symptoms, the initial management comprised targeted medical therapy in four (18%), complete closure in four (18%), and partial closure in 14 patients (63.6%). In the four patients who had a high PVR and negative vasoreactivity, the PVR decreased and vasoreactivity increased after targeted medical therapy; three of these patients underwent cardiac surgery later. Finally, 11 (50%) received targeted medical therapy and 21 patients (95.4%) underwent cardiac surgery. Complete closure resulted in six patients and partial closure in 17 patients. Mortality was observed in two patients. The other 19 patients (91%) had New York Heart Association functional class I.

Conclusion: Targeted medical therapy may be effective in reducing PVR in patients with congenital heart disease and borderline PVD. A stepwise approach may help to achieve improved outcomes in these patients. (Korean Circ J 2015;45(5):408-415)

KEY WORDS: Pulmonary hypertension; Congenital heart defect; Vasodilators; Pulmonary vascular resistance.

Introduction

Despite remarkable advances in cardiac surgery and intervention that have allowed repair of congenital heart defects, pulmonary arterial hypertension (PAH) associated with congenital heart disease remains a major problem. In principle, closure of a large shunt lesions in patients with severe pulmonary hypertension should be performed during early childhood because the patients will progress to an irreversible state with time.

In the past decade, several types of pulmonary vasodilators that can decrease pulmonary arterial pressure have been introduced and have shown promising results. These pulmonary vasodilators appear to be effective in reducing the pulmonary vascular resistance and improving symptoms. Interestingly, this might reverse pulmonary vascular remodelling and enable closure of congenital septal defects in patients previously thought to be in an irreversible or an inoperable state.

We retrospectively analyzed our experience of the stepwise management using targeted medical therapy and surgical/
Interventional closure in patients with congenital heart disease and severe PAH.

**Subjects and Methods**

From February 2000 to March 2011, 22 patients with congenital septal defects and severe PAH were managed in Sejong General Hospital. They had borderline pulmonary vascular disease and the pulmonary vascular resistance (PVR) was from 6 to 16 wood units (WU·m⁻²) and/or the pulmonary arterial pressure was more than two-thirds that of the systemic pressure. In cardiac catheterization, pulmonary flow (Qp) was calculated by oxygen consumption divided by oxygen content difference between pulmonary vein and pulmonary artery. PVR was calculated by transpulmonary pressure gradient divided by pulmonary flow (Qp). The diagnosis was atrial septal defect (ASD) in 7 patients, ventricular septal defect (VSD) in 6 patients, patent ductus arteriosus (PDA) in 4 patients, atrioventricular septal defect in 4 patients, and VSD type of double outlet right ventricle in 1 patient.

The median age of patients was 16 years (range, 9 months–46 years). Eleven patients (50%) of patients had Down’s syndrome. The median follow-up duration from the time of diagnosis was 7.4 years (range, 1.4–11.7 years).

Cardiac catheterization was performed in all patients to evaluate the pulmonary hypertension and to determine operability or acceptability of undergoing defect closure.

Based on the biventricular physiology, a patient with a PVR <about 6 WU was considered operable or acceptable for undergoing closure of the defects at our center. In patients with a PVR >6 WU, we usually performed the pulmonary vasoreactivity test with oxygen and patients who showed a decrease in the final PVR to about 6 WU were considered operable or acceptable for undergoing closure of the defects. The vasoreactivity test was done using oxygen (10 L/min) supplied by mask for 10 min and PVR was calculated in consideration of dissolved oxygen in plasma. Sometimes the balloon occlusion test was performed immediately before complete closure of the defects to confirm the hemodynamic stability after closure and the possible post-procedural outcome. Every decision was taken after an in-depth discussion with pediatric cardiologists and cardiac surgeons at our center. If it was difficult to arrive at a decision of closing the defect, we avoided prompt closure of the defect and repeated cardiac catheterization.

Initial management was selected on an individual basis according to the clinical symptoms and hemodynamic data, such as pulmonary arterial pressure (PAP), PVR, and ratio of pulmonary flow/systemic flow (Qp/Qs). The stepwise approach was performed very slowly and cautiously using targeted medical therapy and surgical/interventional closure (Fig. 1). The targeted medical therapy included phosphodiesterase type-5 inhibitor (sildenafil), endothelin receptor antagonist (bosentan), and/or oral prostanooid (beraprost) as monotherapy or combined therapy.

In this study, we analysed the outcome after dividing the patients into 3 groups according to the initial management. Group 1 included 4 patients (18%) who underwent complete closure of the septal defect. Group 2 included 14 patients (63.6%) who underwent partial closure of the septal defect or patch closure of the septal defect leaving a fenestration. Group 3 included 4 patients (18%) who received medical therapy with pulmonary vasodilators.

This study was approved by the Institutional Review Board of Sejong General Hospital and the requirement for informed consent was waived. Data were expressed as mean±standard deviation or median with ranges for continuous variables.

**Results**

The diagnoses and the age of patients in each group are presented in Table 1. The patients with a right-to-left shunt or a bidirectional shunt suggesting a more advanced pulmonary vascular disease were more frequently observed in Group 3 compared to the other groups. The patients who had Down’s syndrome were more frequently observed in Group 1 and Group 2 than in Group 3.

PVR in patients of Group 1 was relatively lower when measured in room air than that in other groups, and decreased markedly to less than 6 WU on the vasoreactivity test (Fig. 2A and B). However, Group 2 and Group 3 showed higher PVR and a partial or no response to pulmonary vasodilator. The amount of a left-to-right shunt (Qp/Qs) was higher in Group 1 compared to Group 2 and Group 3.
Among the patients in Group 1 who underwent complete closure of septal defects, 3 patients underwent surgical closure of ventricular septal defect (VSD), atrioventricular septal defect (AVSD), and PDA; and 1 patient underwent percutaneous closure of PDA. There was no mortality and the New York Heart Association (NYHA) Functional Class was improved in all of the patients. After defect closure, the mean ratio of peak right ventricular pressure/peak aortic pressure increased. Overall, the treatment was associated with improved outcomes and reduced pulmonary vascular resistance.

Group 3 (Fig. 2C).

Among the patients in Group 1 who underwent complete closure of septal defects, 3 patients underwent surgical closure of ventricular septal defect (VSD), atrioventricular septal defect (AVSD), and PDA; and 1 patient underwent percutaneous closure of PDA. There was no mortality and the New York Heart Association (NYHA) Functional Class was improved in all of the patients. After defect closure, the mean ratio of peak right ventricular pressure/peak aortic pressure increased. Overall, the treatment was associated with improved outcomes and reduced pulmonary vascular resistance.

**Table 1.** Group characteristics

| Total (n=22) | Group 1 (n=4) Complete closure | Group 2 (n=14) Partial closure | Group 3 (n=4) Targeted medical therapy |
|-------------|-------------------------------|-------------------------------|---------------------------------------|
| Median age (years) | 21.3 | 18.8 | 19.3 |
| Diagnosis (n) | PDA (2), AVSD (1), VSD (1) | ASD (6), VSD (5), AVSD (2), DORV (1) | PDA (2), VSD (1), AVSD (1) |
| Shunt direction on echo | Bidirectional (25%), L→R (75%) | Bidirectional (29%), L→R (71%) | Bidirectional (50%), L→R (50%) |
| Down syndrome, n (%) | 3 (75) | 7 (50) | 1 (25) |

PDA: patent ductus arteriosus, AVSD: atrioventricular septal defect, VSD: ventricular septal defect, ASD: atrial septal defect; DORV: double outlet right ventricle, L→R, left to right

**Fig. 2.** Comparison of pulmonary vascular resistance between the three groups. (A) Pulmonary vascular resistance measured in room air. (B) Pulmonary vascular resistance after 100 % oxygen inhalation. (C) Amount of left-to-right shunt (Qp/Qs). Qp/Qs: systemic flow amount/pulmonary flow amount, Rp: pulmonary resistance, WU: wood unit.
Table 2. Baseline demographic and clinical characteristics of Group 3 (n=4)

| Case | Age (years) | Diagnosis | Shunt direction on echo | Cardiac catheterization (vasodilator) | Drug (medication duration until first surgery) |
|------|-------------|-----------|-------------------------|-------------------------------------|-----------------------------------------------|
| 1    | 21          | AVSD, FC II, Down | Bidirectional shunt | SpO2 (%) | p(RV/Ao) | Qp/Qs | PVR (WU·m²) |
|      |             |           |                         | 88       | 0.95     | 1.4 (2.5) | 13.1 (7.5) |
| 2    | 38          | PDA, FC III | Bidirectional shunt, RV dysfunction | 94       | 1        | 1.6 (3)   | 29 (20)    |
| 3    | 12          | PDA       | Bidirectional shunt     | 90       | 0.9      | 1.6 (-)   | 15.1 (-)   |
| 4    | 7           | VSD       | Bidirectional shunt     | 96       | 1        | 1.7 (3.2) | 16.5 (9.4) |

SpO₂: oxygen saturation, p(RV/Ao): ratio of peak pulmonary arterial pressure/peak aortic pressure, Qp/Qs: systemic flow amount/pulmonary flow amount, PVR: pulmonary vascular resistance, WU: wood unit, AVSD: atrioventricular septal defect, FC: functional class, PDA: patent ductus arteriosus, RV: right ventricle, VSD: ventricular septal defect, PA: pulmonary artery.

Fig. 3. Change in pulmonary vascular resistance after partial closure and subsequent targeted medical therapy in group 2. Only 5 patients in group 2 underwent the follow up cardiac catheterization. PVR: pulmonary vascular resistance, ASD: atrial septal defect, VSD: ventricular septal defect.

In Group 2, 14 patients underwent partial closure of septal defects or patch closure of orific defects leaving a fenestration that functioned as a pop-off valve. Fenestration creation of atrial septum was performed in 5 patients with VSD or PDA. Partial ASD closure was performed in 9 patients, partial VSD closure was performed in 2 patients, and partial closure of PDA by banding was performed in 1 patient. There was one case of early mortality that developed bacterial pneumonia and severe pulmonary hypertension after surgery and the patient eventually died of septic shock. The other patients showed postoperative p(PA/Ao) or p(RV/Ao) of <0.5. Still persistent PAH after surgical management necessitated subsequent medical therapy in 5 patients who underwent follow-up cardiac catheterization at 4.45 years later after partial closure in Group 2 (Fig. 3).

Group 3 included one case of complete AVSD, 2 cases of PDA, and one case of VSD. Because these patients had unfavorable hemodynamic data and poor vasoreactivity, and seemed to be in an inoperable clinical state, they initially received targeted medical therapy without cardiac surgery (Table 2). In this group, the patients showed a low Qp/Qs and a high PAH that did not change with administration of pulmonary vasodilation. They also showed mild resting desaturation, consistent with right-to-left shunting on echocardiography before the initiation of targeted medical therapy. Generally, we performed follow-up cardiac catheterization annually or biennially. The mean duration from targeted medical therapy to closure of defects was 3.6 years (range, 15–96 months). Several years later, the direction of the shunt changed to a purely left-to-right shunt on echocardiography and the PVR decreased and Qp/Qs increased on serial cardiac catheterizations. These patients underwent successful closure of defects and subsequent long-term targeted medical therapy with the expectation of a further decrease in the PVR. All patients showed a decrease in PVR after targeted medical therapy (Fig. 4A) compared to baseline data. As well, PVR after administration of pulmonary vasodilators for vasoreactivity test was decreased markedly up to the acceptable level to perform the septal defect closure (Fig. 4B). In addition, the mean Qp/Qs increased from 1.6 to 3.6 (Fig. 4C), and chest X ray showed increase in the cardiomegaly. Of these patients, 3 underwent surgical partial closure of defects (PDA and VSD) or ASD fenestration, and 1 underwent pulmonary arteriety banding. The p(PA/Ao) or p(RV/Ao) was 0.3 in the PDA patient, 0.5 in the VSD patient, and 0.7 in the PA banding patient. Patients who underwent cardiac surgery showed improvement in the NYHA functional class.

Two years later, 2 patients underwent percutaneous closure using the Amplatz device (Mendelsohn Avenue Golden Valley, MN, USA) after confirmation of safety with balloon test occlusion of the
residual fenestration. Fig. 5 shows the serial changes in PVR over time after the combined therapy including pulmonary vasodilator medications, cardiac surgery and subsequent percutaneous closure of residual defect in these 2 patients who were previously considered to be in an irreversible state of pulmonary vascular disease. PVR was markedly decreased after targeted medical therapy with pulmonary vasodilators and did not increase again, even after subsequent surgical and percutaneous closure. One patient plans to undergo follow-up cardiac catheterization, and another patient is being treated with pulmonary vasodilators and is awaiting to undergo percutaneous complete septal defect closure in the future.

There was one case of early mortality (4.5%), and there was one case of late mortality (4.7%), which was related to aggravation of systemic lupus erythematosus. All patients showed improvement in the NYHA functional class (FC); FC I was seen in 90% of patients (n=18) and FC 2 was seen in 10% of patients (n=2). Eventually, complete closure of septal defects was achieved in 36.8% of patients (n=7), and partial closure of septal defects or closure of septal defects leaving a fenestration was achieved in 63.2% of patients (n=12). During the management, 50% of patients (n=11)
were given pulmonary vasodilators as a preoperative conditioning therapy and/or as postoperative long-term therapy for residual pulmonary hypertension. Twenty percent of patients (n=4) of patients required continuous medication with pulmonary vasodilators because of residual pulmonary hypertension.

Discussion

A recent major breakthrough in the treatment of patients with PAH has been the availability of oral endothelin antagonists and the application of sildenafil, a type-5 phosphodiesterase inhibitor. The decision to perform closure of congenital septal defects largely depends on the amount of the shunt and the status of pulmonary circulation. The early repair of large septal defects in patients with severe pulmonary hypertension is crucial to prevent irreversible pulmonary vascular changes. Patients diagnosed with septal defects later in life and those with pulmonary vascular disease are at a high risk of sustained pulmonary hypertension, right heart failure, and hypertensive crisis immediately after surgery. Right-to-left shunting in the presence of severe pulmonary hypertension sustains the cardiac output at the expense of arterial hypoxemia, and is a mechanism for decreasing the right heart pressure in the presence of right ventricular failure. Generally, when right-to-left shunting with cyanosis is present, one has to seriously question the indications and safety of septal defect closure.

In the past, operability or acceptability to undergo septal defect closure was often decided based on pathological findings in lung biopsy. Nowadays, the decision is based more on the severity of pulmonary hypertension and the degree of vasoreactivity of the pulmonary circulation with the use of pulmonary vasodilators. An acute reduction in the mean pulmonary arterial pressure >10 mmHg with a resultant mean pulmonary arterial pressure of ≤40 mmHg without a fall in the cardiac output is considered a positive vasoreactive response in adult. However, positive vasoreactivity does not indicate operability and evaluation of this criteria has not been studied adequately in children with congenital heart disease. In the present study, the possible operable state was defined as a baseline PVR <about 6 WU or a decrease in the final PVR after the administration of pulmonary vasodilators to <about 6 WU.

There have been significant advances in the development of therapies for PAH. Before 1996, treatment options for PAH were limited to conventional therapies including digoxin, diuretics, anticoagulation, supplemental oxygen whenever indicated, calcium channel blockers in selected patients, and lung or heart-lung transplantation. Intravenous epoprostenol was then included in the treatment algorithm for PAH as a bridge to transplantation. Over the past decade, prostacyclin analogues, selective and nonselective endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors have been introduced. Potent oral pulmonary vasodilators that allow long-term administration have become available with promising results. These targeted PAH medical therapies might have the potential to reduce the pulmonary vascular resistance, lower the perioperative risk and possibly widen the range of cases amenable to repair. In this study, 4 patients who were initially considered as inoperable underwent successful closure of defects after achieving acceptable PVR following the targeted medical therapy.

Irreversible pulmonary vascular obstructive disease increases the perioperative risk, lowers the chances of benefiting from the procedure, and increases the risk of postoperative right ventricular failure. Nevertheless, despite the presence of long-standing pulmonary vascular disease with evidence of significant vascular remodelling/abruption, Eisenmenger patients often respond favorably to advanced therapy. Also, it has been suggested that certain pulmonary vasodilators have antiproliferative effects that cause reverse remodeling in the pulmonary circulation. In this study, the response to chronic vasodilator therapy suggests that PAH-targeted therapy may play the role of a conditioning therapy in carefully selected patients with a possible late septal defect.
congenital heart disease and borderline pulmonary vascular disease in Fig. 6. Judicious decision-making and close follow-up of patients are necessary because the long-term efficacy of targeted medical therapy for PAH is not yet known, and tolerability of long-term administration of this therapy has not been established.23) The diagnostic and therapeutic management for patients with congenital heart disease and borderline pulmonary vascular disease should be careful and tailored to the individuals. Also, long-term and continuous monitoring for them is required.

References

1. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243–78.
2. Farber HW, Lascalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655–65.
3. McLaughlin WJ, Gentzler DE, Pannell MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273–7.
4. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858–65.
5. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of pulmonary hypertension with associated congenital heart defects. Circulation 2001;103:1193–8.
6. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970;4:23–30.
7. Jin H, Yang J, Zhang Q, Du J. Epidemiology and clinical management of pulmonary hypertension in children. Korean Circ J 2012;42:513–8.
8. Dimopoulos K, Peset A, Gatoulias MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008;129:163–71.
9. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease—long-term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:1037–42.
10. Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107–22.
11. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative

http://dx.doi.org/10.4070/kcj.2015.45.5.408
11. Test (INOP Test I): the INOP Test Study Group. Circulation 2002;106(12 Suppl 1):76-81.
12. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
13. Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D117-26.
14. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
15. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
16. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7.
17. Frost AE, Quiñones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24:501-3.
18. Yamauchi H, Yamaki S, Fujii M, Iwaki H, Tanaka S. Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect. Ann Thorac Surg 2001;72:905-6; discussion 906-7.
19. Eicken A, Balling G, Gildein HP, Genz T, Kämmerer H, Hess J. Transcatheter closure of a non-restrictive patent ductus arteriosus with an Amplatzer muscular ventricular septal defect occluder. Int J Cardiol 2007;117:e40-2.
20. Khan SA, Gelb BD, Nguyen KH. Evaluation of pulmonary artery banding in the setting of ventricular septal defects and severely elevated pulmonary vascular resistance. Congenit Heart Dis 2006;1:244-50.
21. Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J 2007;153(4 Suppl):81-4.
22. Allcock RJ, O'Sullivan JJ, Corris PA. Atrial septostomy for pulmonary arterial hypertension. Heart 2003;89:1344-7.
23. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007;93:974-6.